The economics of immunosuppression in renal transplantation: a review of recent literature
- 1 February 1999
- journal article
- review article
- Published by Elsevier in Transplantation Proceedings
- Vol. 31 (1-2) , 1328-1332
- https://doi.org/10.1016/s0041-1345(98)02017-x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN KIDNEY TRANSPLANT PATIENTS RECEIVING TACROLIMUS (FK506)-BASED VERSUS CYCLOSPORINE-BASED IMMUNOSUPPRESSION1,2Transplantation, 1997
- MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1Transplantation, 1997
- Modelling in Ecomomic Evaluation: An Unavoidable Fact of LifeHealth Economics, 1997
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- A cost-effectiveness analysis of okt3 induction therapy in cadaveric kidney transplantationAmerican Journal of Kidney Diseases, 1996
- THE RELATIVE EFFECTS OF FK506 AND CYCLOSPORINE ON SHORT- AND LONG-TERM KIDNEY GRAFT SURVIVAL1,2,3Transplantation, 1995
- Developing the Health Care MarketThe Economic Journal, 1991
- A cost-effectiveness analysis of the treatment of chronic renal failureApplied Economics, 1981
- Cost Effectiveness Analysis Applied to the Treatment of Chronic Renal DiseaseMedical Care, 1968